Previous investigations have demonstrated that tumor protein 53 (TP53) mutation has a negative prognostic role in the NSCLC patients (Lee et al., 2015; Deben et al., 2016; Zhao et al., 2019; Qin et al., 2020). This evidence concerns the gene TP53 and non-small cell lung carcinoma.